Mechanistic insights into the inhibition of prostate specific antigen by β-lactam class compounds

Proteins: Structure, Function and Genetics

Volumn 70, Issue 4, 2008, Pages 1416-1428

  Singh, Pratap ^a,b,e   Williams, Simon A ^b   Shah, Meha H ^c   Lectka, Thomas ^c   Pritchard, Gareth J ^d   Isaacs, John T ^b   Denmeade, Samuel R ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Covalent inhibitors; Docking; GOLD; Homology model; MALDI TOF; Serine proteases

Indexed keywords

BETA LACTAM DERIVATIVE; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CARCINOGENESIS; COMPUTER PROGRAM; COVALENT BOND; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN FUNCTION; SCORING SYSTEM; SEQUENCE HOMOLOGY; STEREOCHEMISTRY; TIME; VALIDATION PROCESS;

BETA-LACTAMS; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MALE; METHODS; MODELS, MOLECULAR; PROSTATE-SPECIFIC ANTIGEN; PROTEIN BINDING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 39749093736     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21676     Document Type: Article

References (28)

1. Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin Biochem 2003;36:443-452.
2. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76: 1899-1903.
3. 2+, a tight-binding inhibitor. Prostate 2000;45:132-139.
4. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of "-seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nippon Hoigaku Zasshi 1971;25:322-324.
5. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2006;67:312-329.
6. Gygi CM, Leibovitch IY, Adlington R, Baldwin JE, Chen B, McCoull W, Pritchard GJ, Becker GW, Dixon EP, Little SP, Sutkowski DM, Teater C, Neubauer BL. Prostate-specific antigen (PSA)-mediated proliferation, androgenic regulation and inhibitory effects of LY312340 in HOS-TE85 (TE85) human osteosarcoma cells. Anticancer Res 2002;22:2725-2732.
7. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
8. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940-947.
9. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91:1635-1640.
10. Adlington RM, Baldwin JE, Becker GW, Chen B, Cheng L, Cooper SL, Hermann RB, Howe TJ, McCoull W, McNulty AM, Neubauer BL, Pritchard GJ. Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen. J Med Chem 2001;44:1491-1508.
11. Aoyama Y, Uenaka M, Kii M, Tanaka M, Konoike T, Hayasaki-Kajiwara Y, Naya N, Nakajima M. Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors. Bioorg Med Chem 2001;9:3065-3075.
12. Aoyama Y, Uenaka M, Konoike T, Hayasaki-Kajiwara Y, Naya N, Nakajima M. Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett 2001;11:1691-1694.
13. Doherty JB, Ashe BM, Argenbright LW, Barker PL, Bonney RJ, Chandler GO, Dahlgren ME, Dorn CP, Jr, Finke PE, Firestone RA, Fletcher D, Hagmann WK, Mumford R, O'Grady L, Maycock AL, Pisano JM, Shah SK, Thompson KR, Zimmerman M. Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase. Nature 1986;322:192-194.
14. Wilmouth RC, Kassamally S, Westwood NJ, Sheppard RJ, Claridge TD, Aplin RT, Wright PA, Pritchard GJ, Schofield CJ. Mechanistic insights into the inhibition of serine proteases by monocyclic lactams. Biochemistry 1999;38:7989-7998.
15. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-4930.
16. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998;5:475-488.
17. Villoutreix BO, Lilja H, Pettersson K, Lovgren T, Teleman O. Structural investigation of the α-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Protein Sci 1996;5: 836-851.
18. Hartshorn MJ, Verdonk ML, Chessari G, Brewerton SC, Mooij WT, Mortenson PN, Murray CW. Diverse, high-quality test set for the validation of protein-ligand docking performance. J Med Chem 2007;50:726-741.
19. Nissink JW, Murray C, Hartshorn M, Verdonk ML, Cole JC, Taylor R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002;49:457-471.
20. France S, Shah MH, Weatherwax A, Wack H, Roth JP, Lectka T. Bifunctional Lewis acid-nucleophile-based asymmetric catalysis: mechanistic evidence for imine activation working in tandem with chiral enolate formation in the synthesis of beta-lactams. J Am Chem Soc 2005;127:1206-1215.
21. France S, Wack H, Hafez AM, Taggi AE, Witsil DR, Lectka T. Bifunctional asymmetric catalysis: a tandem nucleophile/Lewis acid promoted synthesis of β-lactams. Org Lett 2002;4:1603-1605.
22. Danelon GO, Laborde M, Mascaretti OA, Boggio SB, Roveri OA. Synthesis and β-lactamase inhibitory activity of 6-fluoropenicillanic acids. Bioorg Med Chem 1993;1:447-455.
23. Han WT, Trehan AK, Wright JJ, Federici ME, Seiler SM, Meanwell NA. Azetidin-2-one derivatives as inhibitors of thrombin. Bioorg Med Chem 1995;3:1123-1143.
24. Ogilvie WW, Yoakim C, Do F, Hache B, Lagace L, Naud J, O'Meara JA, Deziel R. Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease. Bioorg Med Chem 1999; 7:1521-1531.
25. Wilmouth RC, Westwood NJ, Anderson K, Brownlee W, Claridge TD, Clifton IJ, Pritchard GJ, Aplin RT, Schofield CJ. Inhibition of elastase by N-sulfonylaryl β-lactams: anatomy of a stable acyl-enzyme complex. Biochemistry 1998;37:17506-17513.
26. Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, Ogletree ML, Slusarchyk WA, Zahler R, Seiler SM, Bisacchi GS. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 2004;14: 2233-2239.
27. Radisky ES, Koshland DE, Jr. A clogged gutter mechanism for protease inhibitors. Proc Natl Acad Sci USA 2002;99:10316-10321.
28. Radisky ES, Lee JM, Lu CJ, Koshland DE, Jr. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proc Natl Acad Sci USA 2006;103:6835-6840.